EGFR and non-small cell lung carcinoma: With advances in genetic testing technologies, studies in NSCLC have demonstrated that molecularly targeted therapies based on driver gene mutations offer significant survival advantages compared to traditional chemotherapy, particularly therapies targeting mutations in EGFR (13, 14).